RIGL at a glance
RIGEL PHARMACEUTICALS INC (RIGL, SEC CIK 1034842) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and Form 4 insider filings as recently as September 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), RIGEL PHARMACEUTICALS INC (RIGL) reported revenue of $294.3 million (up 64.1% from FY2024) and net income of $367.0 million. Diluted EPS was $19.48.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $294.3M
- +64.1% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- Latest 8-K
- Aug 4, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Six-month revenue: TAVALISSE $84.7M, up 24% from $68.5M YoY
- Best performer: REZLIDHIA sales $17.0M, up 29% from $13.1M YoY
- Worst performer: GAVRETO sales $20.3M, down 2% from $20.8M YoY
- Capital deployment: $70.0M VEPPANU upfront payment and $40.0M revolving-credit borrowing at June 30, 2026
- Outlook: VEPPANU commercial availability expected mid-August 2026; R289 dose-expansion enrollment completion expected second half 2026
Risk Factors
- Newly added VEPPANU transition risk, triggered by June 11, 2026 license effectiveness following early HSR Act termination
- Most materially updated operational risk, with Arvinas and Pfizer retaining responsibilities before transfer and development funding capped at $40.0 million
- Compliance exposure from VEPPANU agreement, including anti-corruption, trade-controls and sanctions obligations with expedited termination provisions
- Near-term commercialization risk from manufacturing transfer delays, limited capacity and supply-chain disruptions affecting VEPPANU launch execution
- Financial risk from VEPPANU milestone payments and tiered royalties, potentially reducing product profitability
AI summary of the RIGL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 provides no operating or financial results; substantive information appears limited to the accompanying exhibit
- Disclosure is furnished rather than filed, limiting liability under Exchange Act Section 18 and Securities Act Sections 11 and 12(a)(2)
Item EX-99.1: Item EX-99.1
- Q2 revenue $78.7M, with product sales $67.0M up 14%; TAVALISSE led growth at $47.4M, up 18%
- Net income $17.3M versus $59.6M, reflecting prior-year $40.0M non-cash Lilly collaboration revenue
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Alison L. Hannah appointed Executive Vice President and Chief Medical Officer effective July 1, 2026
- Hannah resigned from Rigel’s Board upon appointment, ending service that began in May 2021
Item 2.01: Completion of Acquisition or Disposition of Assets
- Rigel completed acquisition of exclusive global rights to develop, manufacture, and commercialize VEPPANU™ (vepdegestrant)
- $70.0 million upfront payment made to Arvinas, Arvinas affiliates, and Pfizer
AI summaries of RIGL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RIGL
Don't miss the next RIGL filing
- Alerts as it files. A push when RIGL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RIGL, by share count.
- Ask anything. An AI agent that reads every RIGL filing and answers with sources.
RIGL alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Schorno Dean L | M | Sep 2, 2026 | 620 | $18.70 |
| Schorno Dean L | M | Sep 2, 2026 | 2,000 | - |
| Schorno Dean L | M | Sep 2, 2026 | 1,286 | - |
| Schorno Dean L | M | Sep 2, 2026 | 2,000 | $24.20 |
| Schorno Dean L | M | Sep 2, 2026 | 620 | - |
| Schorno Dean L | M | Sep 2, 2026 | 694 | - |
| Schorno Dean L | M | Sep 2, 2026 | 694 | $12.70 |
| Schorno Dean L | M | Sep 2, 2026 | 1,286 | $24.20 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $116.9M | $179.3M | $294.3M |
| Operating Income | - | $24.2M | $125.5M |
| Net Income | -$25.1M | $17.5M | $367.0M |
| Op. Margin | - | 13.5% | 42.6% |
| Net Margin | -21.5% | 9.8% | 124.7% |
| Balance Sheet | |||
| Total Assets | $117.2M | $164.0M | $513.6M |
| Equity | -$28.6M | $3.3M | $391.5M |
| ROE | 87.6% | 531.8% | 93.8% |
| Per Share | |||
| EPS | $-0.14 | $0.99 | $19.48 |
| Cash Flow | |||
| Operating CF | -$5.7M | $31.5M | $75.7M |
Source: XBRL data in RIGEL PHARMACEUTICALS INC (RIGL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
RIGL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 10, 2026 | - | - | - |
| 8-K | Jul 1, 2026 | - | Analysis | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 17, 2026 | - | Analysis | - |
| 4 | May 28, 2026 | - | - | |
| 8-K | May 20, 2026 | - | Analysis | |
| SC 13G | May 15, 2026 | - | - | |
| 8-K | May 12, 2026 | - | Analysis | |
| SC 13G | May 7, 2026 | - | - | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 21, 2026 | - | Analysis | - |
| 10-K | Mar 3, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 3, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
RIGL SEC filings: frequently asked questions
What was RIGL's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), RIGEL PHARMACEUTICALS INC (RIGL) reported revenue of $294.3 million (up 64.1% from FY2024) and net income of $367.0 million. Diluted EPS was $19.48. The figures come from the XBRL data in the 10-K.
What did RIGL report in its latest 8-K?
RIGEL PHARMACEUTICALS INC (RIGL) filed an 8-K on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Item 2.02 provides no operating or financial results; substantive information appears limited to the accompanying exhibit.
What are the latest RIGL SEC filings?
RIGEL PHARMACEUTICALS INC (RIGL) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and a Form 4 insider filing on September 3, 2026.
What is RIGL's SEC CIK number?
RIGEL PHARMACEUTICALS INC (RIGL)'s SEC Central Index Key (CIK) is 1034842. EDGAR lists every RIGL filing under that number.
Ask anything about RIGL
The research agent reads RIGL's filings, financials, insider trades and 13F holders, then answers with sources.